Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2Plasma cell 1Dermatologic 1

Conditions

Lung Neoplasms 9Ovarian Neoplasms 4Carcinoma, Hepatocellular 4Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large B-Cell, Diffuse 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Resectable Intrahepatic Cholangiocarcinoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Papillary renal cell carcinoma, sporadic 1

Interventions

venetoclax 27fludarabine 26Cyclophosphamide 25Specimen Handling 20Azacitidine 20Biopsy 15Whole-Body Irradiation 14Cytarabine 14Stem Cell Transplantation 13Decitabine 13Tacrolimus 12Melphalan 12fludarabine phosphate 11Mycophenolic Acid 11Busulfan 11Injections 9X-Rays 7Thiotepa 7Hematopoietic Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 7decitabine and cedazuridine drug combination 6Cyclosporine 6ruxolitinib 5Magnetic Resonance Spectroscopy 5Idarubicin 5Filgrastim 5gilteritinib 4Sirolimus 4Peripheral Blood Stem Cell Transplantation 4Cyclosporins 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Myelodysplastic Syndromes × Disulfides × Clear all
NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic

Phase 1 Recruiting
127 enrolled
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT06815003 2025-06-27

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

Phase 2 Recruiting
35 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡